Completed PHASE1 INTERVENTIONAL 1-arm NCT05518357

LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

An Exploratory Clinical Study on the Safety and Efficacy of LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Sponsor: Hebei Yanda Ludaopei Hospital

Conditions Relapsed/Refractory Acute Myeloid Leukemia

Interventions LILRB4 STAR-T

Updated 5 times since 2022 Last updated: Jan 11, 2023 Started: Jun 24, 2022 Primary completion: Nov 15, 2022 Completion: Nov 15, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Relapsed/Refractory Acute Myeloid Leukemia, this trial is completed. The trial is conducted by Hebei Yanda Ludaopei Hospital and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Nov 2022 — Feb 2023 [monthly]

Recruiting PHASE1
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE1

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebei Yanda Ludaopei Hospital

Data source: Hebei Yanda Ludaopei Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sanhe, China